A recent study demonstrated that brusatol could inhibit the malignant behaviors of colon cancer by upregulating ARRDC4 expression-a cancer glycolytic inhibitor- while modulating PI3K/YAP1/TAZ pathway [37]. Here, ARRDC4 is linked to colonic neoplasm.